Childhood Cancers

Latest News


Tasigna (nilotinib) was granted Food and Drug Administration (FDA) approval, to be used in the first- and second-line setting for pediatric patients 1 year old or older who have Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).

Ryan Hamner has battled Hodgkin lymphoma four times since the age of 5, and has had some interesting hobbies since - from gardening to metal detecting. But for Hamner, two things stuck: music and creativity.

Sprycel (dasatinib), an oral medication that helps reduce the production of damaged white blood cells, has been approved by the Food and Drug Administration for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.